Literature DB >> 2670577

Neuropeptides: animal behaviour and human psychopathology.

D de Wied1, J M van Ree.   

Abstract

Animal studies have demonstrated that neuropeptides modulate nervous system functions. It has been postulated that disturbances in neuropeptide systems may be aetiological factors in psychiatric and neurological disorders. Neuropeptides related to ACTH/MSH, including ORG 2766, increase motivation and attention and facilitate recovery processes after nerve damage. These peptides may be effective during the early stage of dementia. Vasopressin and related peptides improve memory processes in animals and humans. In addition, these peptides influence social behaviour, mood and addictive behaviour. The non-opioid gamma-type endorphins have neuroleptic-like activities in animals and antipsychotic effects in a category of schizophrenic patients. Peptides related to CCK have also been found to be effective in these patients. Some neuropeptides, e.g. TRH and PLG, have been reported to exert antidepressant effects. Further research may eventually produce neuropeptides with therapeutic action in psychiatric and neurological diseases.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2670577     DOI: 10.1007/bf00449813

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Neurol Sci        ISSN: 0175-758X


  46 in total

1.  Neural functions of TRH.

Authors:  S Reichlin
Journal:  Acta Endocrinol Suppl (Copenh)       Date:  1986

2.  gamma-Endorphin and schizophrenia: amino acid composition of gamma-endorphin and nucleotide sequence of gamma-endorphin cDNA from pituitary glands of schizophrenic patients.

Authors:  R A Bovenberg; J P Burbach; V M Wiegant; G H Veeneman; J H van Boom; P D Baas; H S Jansz; D de Wied
Journal:  Brain Res       Date:  1986-06-18       Impact factor: 3.252

Review 3.  Cholecystokinin and schizophrenia.

Authors:  N P Nair; S Lal; D M Bloom
Journal:  Prog Brain Res       Date:  1986       Impact factor: 2.453

4.  The use of the synthetic peptides gamma-type endorphins in mentally ill patients.

Authors:  J M van Ree; W M Verhoeven; D de Wied; H M van Praag
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

5.  Centrally acting drugs alter in vitro beta-endorphin processing in the rat.

Authors:  T P Davis; H Schoemaker; A J Culling
Journal:  Eur J Pharmacol       Date:  1984-04-20       Impact factor: 4.432

6.  Clinical study on the psychotropic effects of caerulein--an open clinical trial in chronic schizophrenic patients.

Authors:  H Itoh; S Tanoue; G Yagi; M Tateyama; M Kamisada; Y Fujii; M Takamiya; S Nakajima
Journal:  Keio J Med       Date:  1982-10

7.  Effect of (Des-Tyr)-gamma-endorphin in schizophrenia.

Authors:  H Y Meltzer; D A Busch; B J Tricou; A Robertson
Journal:  Psychiatry Res       Date:  1982-06       Impact factor: 3.222

8.  beta-endorphin-(1-27) is an antagonist of beta-endorphin analgesia.

Authors:  R G Hammonds; P Nicolas; C H Li
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

9.  Des-tyrosine-gamma-endorphin administration in chronic schizophrenics. A preliminary report.

Authors:  C A Tamminga; P J Tighe; T N Chase; E G DeFraites; M H Schaffer
Journal:  Arch Gen Psychiatry       Date:  1981-02

10.  Antipsychotic effects of caerulein, a decapeptide chemically related to cholecystokinin octapeptide, on schizophrenia.

Authors:  T Moroji; N Watanabe; N Aoki; S Itoh
Journal:  Int Pharmacopsychiatry       Date:  1982
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.